Chromatographic methods for purification of proteins from plasma
The present invention relates to the field of chromatography. More closely, the invention relates to a chromatographic method for purification of plasmaproteins, such as Factor VIII, von Willebrand factor and Factor IX. The chromatographic method is performed on a matrix comprising an inner porous core and outer porous lid surrounding said core.
1. A chromatographic method comprising the following steps:
loading plasma comprising plasma proteins on a chromatography column packed with a resin comprising porous lid beads having an inner porous core and an outer porous lid, wherein the inner core is provided with anion exchange ligands, and wherein the porosity of the lid and core does not allow entering of molecules larger than 500 kD;
adsorbing Factor IX (FIX) on the anion exchange ligands in the core;
collecting separated plasma proteins in the flow through; and
eluting FIX from the ligands in the core.
2. The method of claim 1 , wherein the anion exchange ligands are selected from diethylaminoethyl (DEAE), quaternary aminoethyl (QAE) or quaternary ammonium (Q).
3. The method of claim 2 , wherein the anion exchange ligands are Q-ligands.
4. The method of claim 1 , wherein other plasma proteins besides FIX are collected in the flow through separated from each other by the sieving effect of the core and shell and comprise Factor VIII (FVIII) and von Willebrand factor (vWF), IgG, human serum albumin (HSA) and Complement C3 (C3).
5. The method of claim 1 , wherein the loading of plasma is repeated 1-20 times, followed by running buffer to obtain a corresponding number of flow throughs (FT's), before the FIX is eluted from the ligands in the core.
6. The method of claim 5 , wherein other plasma proteins besides FIX are collected in the flow through separated from each other by the sieving effect of the core and shell and comprise Factor VIII (FVIII) and von Willebrand factor (vWF), IgG, human serum albumin (HSA) and Complement C3 (C3), and wherein specific fractions of respective FT are pooled to obtain FVIII/vWF, IgG/HSA and C3 respectively.
7. The method of claim 1 , wherein the total lid bead thickness is 40-100 μm in diameter, and the lid thickness is 2-10 μm.
8. The method of claim 1 , wherein the ligand concentration in the core is 50-200 μmol/ml.
9. The method of claim 1 , wherein the lid is provided with affinity ligands, hydrophobic interaction ligands, IMAC ligands, cation exchange ligands or multimodal ligands; and at least one plasma protein other than FIX are adsorbed on the ligands in the lid in the same step as FIX is adsorbed on the ligands in the core; and wherein plasma proteins are sequentially eluted from the ligands in the lid and FIX is eluted from ligands in the core.
10. The method of claim 9 , wherein the ligands in the lid are ligands having immunoglobulin affinity.
11. The method of claim 1 , wherein the lid and core are made of agarose of the same porosity.
12. The method of claim 1 , wherein the porosity of the lid is larger than of the core.
13. The method of claim 1 , wherein the porosity of the lid is smaller than of the core.
14. The method of claim 5 , wherein the loading of plasma is repeated 5-10 times.
15. The method of claim 9 , wherein the at least one plasma protein other than FIX comprises FVIII/vWF, IgG, HSA, or C3.
16. The method of claim 1 , wherein the lid is provided with ligands comprising at least one of Protein A or G or variants thereof.